Back to Search
Start Over
Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats.
- Source :
-
Pediatric research [Pediatr Res] 2021 Feb; Vol. 89 (3), pp. 510-517. Date of Electronic Publication: 2020 May 01. - Publication Year :
- 2021
-
Abstract
- Background: Unconjugated hyperbilirubinemia, a feature of neonatal jaundice or Crigler-Najjar syndrome, can lead to neurotoxicity and even death. We previously demonstrated that unconjugated bilirubin (UCB) can be eliminated via transintestinal excretion in Gunn rats, a model of unconjugated hyperbilirubinemia, and that this is stimulated by enhancing fecal fatty acid excretion. Since transintestinal excretion also occurs for cholesterol (TICE), we hypothesized that increasing fecal cholesterol excretion and/or TICE could also enhance fecal UCB disposal and subsequently lower plasma UCB concentrations.<br />Methods: To determine whether increasing fecal cholesterol excretion could ameliorate unconjugated hyperbilirubinemia, we treated hyperbilirubinemic Gunn rats with ezetimibe (EZE), an intestinal cholesterol absorption inhibitor, and/or a liver X receptor (LXR) and farnesoid X receptor (FXR) agonist (T0901317 (T09) and obeticholic acid (OCA), respectively), known to stimulate TICE.<br />Results: We found that EZE treatment alone or in combination with T09 or OCA increased fecal cholesterol disposal but did not lower plasma UCB levels.<br />Conclusions: These findings do not support a link between the regulation of transintestinal excretion of cholesterol and bilirubin. Furthermore, induction of fecal cholesterol excretion is not a potential therapy for unconjugated hyperbilirubinemia.<br />Impact: Increasing fecal cholesterol excretion is not effective to treat unconjugated hyperbilirubinemia. This is the first time a potential relation between transintestinal excretion of cholesterol and unconjugated bilirubin is investigated. Transintestinal excretion of cholesterol and unconjugated bilirubin do not seem to be quantitatively linked. Unlike intestinal fatty acids, cholesterol cannot "capture" unconjugated bilirubin to increase its excretion. These results add to our understanding of ways to improve and factors regulating unconjugated bilirubin disposal in hyperbilirubinemic conditions.
- Subjects :
- Animals
Bile chemistry
Bile Acids and Salts metabolism
Bilirubin chemistry
Chenodeoxycholic Acid pharmacology
Chenodeoxycholic Acid therapeutic use
Crigler-Najjar Syndrome metabolism
Dietary Fats pharmacokinetics
Ezetimibe pharmacology
Haptoglobins analysis
Hydrocarbons, Fluorinated pharmacology
Intestines drug effects
Intestines metabolism
Lipids blood
Liver X Receptors metabolism
Male
PPAR delta metabolism
Random Allocation
Rats
Rats, Gunn
Receptors, Cytoplasmic and Nuclear metabolism
Sulfonamides pharmacology
Chenodeoxycholic Acid analogs & derivatives
Cholesterol metabolism
Crigler-Najjar Syndrome therapy
Ezetimibe therapeutic use
Feces chemistry
Hydrocarbons, Fluorinated therapeutic use
Hyperbilirubinemia therapy
Sulfonamides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1530-0447
- Volume :
- 89
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Pediatric research
- Publication Type :
- Academic Journal
- Accession number :
- 32357361
- Full Text :
- https://doi.org/10.1038/s41390-020-0926-2